Evidence map›Paper›PMID 38341597›Full record

ReviewVirology journal2024

Nationwide quality assurance of high-throughput diagnostic molecular testing during the SARS-CoV-2 pandemic: role of the Belgian National Reference Centre.

Reile Janssen, Lize Cuypers, Lies Laenen, Els Keyaerts, Kurt Beuselinck, Sunita Janssenswillen, Bram Slechten, Jannes Bode, Elke Wollants, Kristel Van Laethem and 29 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Virology journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

39 authors.

Reile Janssen *National Reference Centre for Respiratory Pathogens, Department of Laboratory Medicine, University Hospitals Leuven, 3000, Leuven, Belgium. reile.janssen@uzleuven.be.
Lize Cuypers *National Reference Centre for Respiratory Pathogens, Department of Laboratory Medicine, University Hospitals Leuven, 3000, Leuven, Belgium.
Lies Laenen *National Reference Centre for Respiratory Pathogens, Department of Laboratory Medicine, University Hospitals Leuven, 3000, Leuven, Belgium.
Els KeyaertsNational Reference Centre for Respiratory Pathogens, Department of Laboratory Medicine, University Hospitals Leuven, 3000, Leuven, Belgium.
Kurt BeuselinckNational Reference Centre for Respiratory Pathogens, Department of Laboratory Medicine, University Hospitals Leuven, 3000, Leuven, Belgium.
Sunita JanssenswillenFederal Testing Platform COVID-19, Department of Laboratory Medicine, University Hospitals Leuven, 3000, Leuven, Belgium.
Bram SlechtenFederal Testing Platform COVID-19, Department of Laboratory Medicine, University Hospitals Leuven, 3000, Leuven, Belgium.
Jannes BodeNational Reference Centre for Respiratory Pathogens, Department of Laboratory Medicine, University Hospitals Leuven, 3000, Leuven, Belgium.
Elke WollantsLaboratory of Clinical and Epidemiological Virology, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, 3000, Leuven, Belgium.
Kristel Van LaethemLaboratory of Clinical and Epidemiological Virology, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, 3000, Leuven, Belgium.
Annabel RectorLaboratory of Clinical and Epidemiological Virology, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, 3000, Leuven, Belgium.
Mandy BloemenLaboratory of Clinical and Epidemiological Virology, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, 3000, Leuven, Belgium.
Anke SijmonsNational Reference Centre for Respiratory Pathogens, Department of Laboratory Medicine, University Hospitals Leuven, 3000, Leuven, Belgium.
Nathalie de SchaetzenNational Reference Centre for Respiratory Pathogens, Department of Laboratory Medicine, University Hospitals Leuven, 3000, Leuven, Belgium.
Arnaud CapronQuality of Laboratories Unit, Scientific Directorate of Biological Health Risks, Sciensano, 1000, Brussels, Belgium.
Kurt Van BaelenJanssen Pharmaceutica N.V, Johnson & Johnson, 2340, Beerse, Belgium.
Thierry PascalGSK Vaccines, 1330, Rixensart, Belgium.
Céline VermeirenUCB Pharma, 1420, Braine L'Alleud, Belgium.
Fabrice BureauLaboratory of Cellular and Molecular Immunology, GIGA Institute, University of Liège, 4000, Liège, Belgium.
Jo VandesompeleBiogazelle, a CellCarta Company, Technologiepark Zwijnaarde, 9052, Zwijnaarde, Belgium.
Pieter De SmetCliniSys|MIPS, 9000, Ghent, Belgium.
Wouter UtenUgenTec N.V, 3500, Hasselt, Belgium.
Hugues MalonneFederal Agency for Medicines and Health Products (FAGG-AFMPS), 1210, Brussels, Belgium.
Pierre KerkhofsFederal Public Service Public Health, Safety of the Food Chain and the Environment, 1210, Brussels, Belgium.
Jo De CockNational Institute for Health and Disability Insurance (RIZIV/INAMI), 1150, Brussels, Belgium.
Veerle MatheeussenFederal Testing Platform COVID-19, University Hospitals Antwerp, 2650, Edegem, Belgium.
Bruno VerhasseltFederal Testing Platform COVID-19, Department of Laboratory Medicine, Ghent University and Ghent University Hospital, 9000, Ghent, Belgium.
Laurent GilletFederal Testing Platform COVID-19, University of Liège, 4000, Liège, Belgium.
Gautier DetryFederal Testing Platform COVID-19, Laboratory of Clinical Biology, Pole Hospitalier Jolimont, 7100, La Louvière, Belgium.
Bertrand BearzattoFederal Testing Platform COVID-19, Centre Des Technologies Moléculaires Appliquées (CTMA), Institute of Experimental and Clinical Research (IREC), Cliniques Universitaires Saint-Luc and Université Catholique de Louvain (UCLouvain), 1200, Brussels, Belgium.
Jonathan DegosserieFederal Testing Platform COVID-19, Department of Laboratory Medicine, CHU UCL Namur, 5530, Yvoir, Belgium.
Coralie HeninFederal Testing Platform COVID-19, Université Libre de Bruxelles, 1070, Brussels, Belgium.
Gregor PairouxQuality of Laboratories Unit, Scientific Directorate of Biological Health Risks, Sciensano, 1000, Brussels, Belgium.
COVID-19 Genomics Belgium Consortium
Piet MaesLaboratory of Clinical and Epidemiological Virology, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, 3000, Leuven, Belgium.
Marc Van RanstNational Reference Centre for Respiratory Pathogens, Department of Laboratory Medicine, University Hospitals Leuven, 3000, Leuven, Belgium.
Katrien LagrouNational Reference Centre for Respiratory Pathogens, Department of Laboratory Medicine, University Hospitals Leuven, 3000, Leuven, Belgium.
Elisabeth DequekerNational Reference Centre for Respiratory Pathogens, Department of Laboratory Medicine, University Hospitals Leuven, 3000, Leuven, Belgium.
Emmanuel AndréNational Reference Centre for Respiratory Pathogens, Department of Laboratory Medicine, University Hospitals Leuven, 3000, Leuven, Belgium.

Funding

Federal Public Service Public Health Belgium COVID-19 testingFonds Wetenschappelijk Onderzoek G0H4420NSciensano (Belgium) NRC
6 · The paper itself

Abstract

Since the onset of the coronavirus disease (COVID-19) pandemic in Belgium, UZ/KU Leuven has played a crucial role as the National Reference Centre (NRC) for respiratory pathogens, to be the first Belgian laboratory to develop and implement laboratory developed diagnostic assays for SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) and later to assess the quality of commercial kits. To meet the growing demand for decentralised testing, both clinical laboratories and government-supported high-throughput platforms were gradually deployed across Belgium. Consequently, the role of the NRC transitioned from a specialised testing laboratory to strengthening capacity and coordinating quality assurance. Here, we outline the measures taken by the NRC, the national public health institute Sciensano and the executing clinical laboratories to ensure effective quality management of molecular testing throughout the initial two years of the pandemic (March 2020 to March 2022).

Indexed as

COVID-19SARS-CoV-2BelgiumClinical Laboratory TechniquesCOVID-19 TestingHumansMolecular Diagnostic TechniquesPandemicsBelgiumCOVID-19High-throughput testingNational reference centreQuality assuranceSARS-CoV-2

Identifiers

PMID38341597
PMCPMC10858549

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.